Pfizer Inc and BioNTech obtained good results vaccinating adolescents aged 12 to 15


Most COVID-19 vaccines being rolled out worldwide are for adults, who are at higher risk from the coronavirus. After conducting trial, – Pfizer Inc and BioNTech SE said on Wednesday their COVID-19 vaccine was safe and effective and produced robust antibody responses in 12 to 15-year olds. n the trial of 2,260 adolescents aged 12 to 15, there were 18 cases of COVID-19 in the group that got a placebo shot and none in the group that got the vaccine, resulting in 100% efficacy in preventing COVID-19. The new study offers the first evidence of how the vaccine will also work in school-age adolescents. The vaccine was well tolerated, with side effects in line with those seen among those aged 16 to 25 in the adult trial. The main side effects are pain, fever, chills and fatigue, particularly after the second dose. The companies are expected to request soon the authorisation in the U.S. and Europe.


This possibly will help schools, at least the upper grades, start to look a little more normal after months of disruption. “It’s hard to get kids to comply with masking and distancing, so something that gives them hard protection and takes them out of the mix of spreading the virus is all for the good,” Dr. Philip J. Landrigan of Boston College said. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected by the middle of this year from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds.